logo-loader
viewParadigm Biopharmaceuticals Ltd

Paradigm's drug developments sees growing market opportunities

Paul Rennie, chief executive for Paradigm Biopharmaceuticals, speaks with Proactive Investors.

Quick facts: Paradigm Biopharmaceuticals Ltd

Price: 2.88 AUD

ASX:PAR
Market: ASX
Market Cap: $653.65 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Alicanto Minerals team reveal ambitious extended drill programme for...

Alicanto Minerals' (ASX:AQI) recently appointed chairman Ray Shorrocks and managing director Peter George discuss with Proactive's Andrew Scott the plans for its flagship project in Sweden. As their main focus George says the project has upwards of 15 targets within 10-15 kilometres of the mine...

14 minutes ago

2 min read